CiRA, Dainippon Sumitomo Pharma and Hitachi prepare for clinical trial on iPS-cell-derived dopamine neural progenitor cells

Jointly with Prof. Atsushi TAKAHASHI of CiRA, DSP and Hitachi have initiated experiments on the mass-production of dopamine neural progenitor cells derived from iPS cells and are preparing for doctor-initiated clinical trial on treatment for Parkinson’s disease in 2018.

Dainippon Sumitomo Pharma news release, July 24, 2015; Nikkei Biotech news release, February 6, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny